Cost Savings of Universal Decolonization to Prevent Intensive Care Unit Infection: Implications of the REDUCE MRSA Trial by Huang, Susan S. et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY OCTOBER 2 0 1 4 , VOL. 3 5 , NO. S3 
O R I G I N A L A R T I C L E 
Cost Savings of Universal Decolonization to Prevent Intensive Care 
Unit Infection: Implications of the REDUCE MRSA Trial 
Susan S. Huang, MD, MPH;' Edward Septimus, MD;2 Taliser R. Avery, MPH;3 Grace M. Lee, MD, MPH;3 
Jason Hickok, MBA, RN;4 Robert A. Weinstein, MD;5 Julia Moody, MS;4 Mary K. Hayden, MD;6 
Jonathan B. Perlin, MD, PhD;4 Richard Piatt, MD, MS;3 G. Thomas Ray, MBA7 
OBJECTIVE. To estimate and compare the impact on healthcare costs of 3 alternative strategies for reducing bloodstream infections in 
the intensive care unit (ICU): methicillin-resistant Staphylococcus aureus (MRSA) nares screening and isolation, targeted decolonization (ie, 
screening, isolation, and decolonization of MRSA carriers or infections), and universal decolonization (ie, no screening and decolonization 
of all ICU patients). 
DESIGN. Cost analysis using decision modeling. 
METHODS. We developed a decision-analysis model to estimate the health care costs of targeted decolonization and universal decolonization 
strategies compared with a strategy of MRSA nares screening and isolation. Effectiveness estimates were derived from a recent randomized 
trial of the 3 strategies, and cost estimates were derived from the literature. 
RESULTS. In the base case, universal decolonization was the dominant strategy and was estimated to have both lower intervention costs 
and lower total ICU costs than either screening and isolation or targeted decolonization. Compared with screening and isolation, universal 
decolonization was estimated to save $171,000 and prevent 9 additional bloodstream infections for every 1,000 ICU admissions. The 
dominance of universal decolonization persisted under a wide range of cost and effectiveness assumptions. 
CONCLUSIONS. A strategy of universal decolonization for patients admitted to the ICU would both reduce bloodstream infections and 
likely reduce healthcare costs compared with strategies of MRSA nares screening and isolation or screening and isolation coupled with 
targeted decolonization. 
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The intensive care unit (ICU) has been a long-standing focus decolonization, and universal decolonization with respect to 
of attention for reducing largely preventable healthcare- their ability to reduce the rate of MRSA-positive clinical cul-
associated infections.13 Many prevention strategies have tures and all-pathogen BSIs in adults. "Screening and isola-
emerged to reduce the prevalence or transmission of anti- tion" was the routine and long-standing strategy in these 
biotic-resistant pathogens, such as methicillin-resistant Staph- hospitals and consisted of screening all patients for MRSA 
ylococcus aureus (MRSA), as well as to reduce bloodstream nasal colonization at admission to the ICU and using contact 
infections (BSIs).4"7 Several of these strategies have evidence precautions for patients with current or previous MRSA col-
of benefit in observational studies, but comparative effec- onization or infection.12 One-third of hospitals were random-
tiveness studies have only recently been published, and com- ized to initiate "targeted decolonization," which involved 
parative cost analyses are lacking.8"11 screening and isolation but added a 5-day decolonization 
Recently, 3 promising strategies were compared in a large, regimen for all known MRSA carriers or patients with MRSA 
cluster-randomized trial (the Randomized Evaluation of De- infection that consisted of twice-daily intranasal mupirocin 
colonization versus Universal Clearance to Eliminate and daily bathing with chlorhexidine-impregnated cloths. An-
[REDUCE] MRSA trial).9 This 43-hospital, 74-ICU trial com- other third of hospitals were randomized to initiate "universal 
pared the effectiveness of screening and isolation, targeted decolonization," in which ICU admission screening for MRSA 
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was stopped, contact precautions were unchanged from the 
other strategies, and all patients received twice-daily intra-
nasal mupirocin for 5 days plus daily bathing with chlor-
hexidine-impregnated cloths for the entire ICU stay. 
The results of the REDUCE MRSA trial indicated that uni-
versal decolonization was more effective than targeted de-
colonization or screening and isolation in reducing BSIs from 
any pathogen. However, the cost implications of these strat-
egies have not been addressed in light of these results. Our 
objective was to estimate the incremental effect on healthcare 
costs associated with targeted decolonization and universal 
decolonization compared with screening and isolation, which 
we considered to be the current standard of care. If either of 
these 2 strategies were found to be less costly than screening 
and isolation, the benefits of implementing one of these strat-
egies would be to not only improve health but also decrease 
use of healthcare resources. 
M E T H O D S 
Decision Analysis Model 
We developed a static decision analysis model, programmed 
in Microsoft Excel, that compared the effects of the above 3 
strategies for preventing infections in adult ICUs: (1) screen-
ing and isolation, (2) targeted decolonization, and (3) uni-
versal decolonization (Table l).9 
Using data from the REDUCE MRSA trial and cost and 
utilization estimates from published sources, we simulated 
the effects of each of the 3 strategies on healthcare costs, ICU 
days, and BSIs for 1 year, assuming a hospital with 1,000 
annual ICU admissions. Because the trial did not measure 
effects outside of the ICU, we only modeled ICU impact. The 
primary perspective was that of the healthcare system. Be-
cause this was strictly a cost analysis, no quality-of-life mea-
sures were incorporated, nor were health states assigned dollar 
values. 
Model Inputs: Percentage of Patients Placed on Contact 
Precautions 
We assumed that the background percentage of patients who 
arrive at the ICU and have test results positive for MRSA or 
have a known recent history of MRSA infection or coloni-
zation was 11% (Table 2). This estimate was based on the 
ICU MRSA importation rate reported from the baseline pe-
riod in all arms of the REDUCE MRSA trial,9 and it remained 
unchanged during the implementation phase for the arms 
that continued screening. For the universal decolonization 
arm, knowledge of MRSA importation decreased in the im-
plementation phase to 4%, likely because of cessation of 
screening and possibly because of effects of decolonization 
for patients readmitted to the ICU. Therefore, under the uni-
versal decolonization strategy, fewer persons were modeled 
as being placed on contact precautions. For this cost analysis, 
it was not necessary to model the "true" percentage of patients 
colonized with MRSA or the relationship between MRSA col-
onization and the rate of BSI. The percentage of patients with 
test results positive for MRSA is primarily important in the 
model because it affects the number of persons who are placed 
on contact precautions and therefore affects costs. For the 
universal colonization strategy, 4% of patients were placed 
on contact precautions (and therefore incurred the associated 
costs) because they had some known history of MRSA col-
onization or infection, but this percentage should not be 
interpreted as directly relating to any "true" colonization rate. 
Model Inputs: Risk of BSI 
Using data from the REDUCE MRSA trial, the baseline in-
cidence of BSI was assumed to be 19.63 cases per 1,000 ICU 
admissions, equivalent to approximately 5 infections per 
1,000 ICU-days (Table 2). The risk of BSI under the 3 different 
strategies was also derived from the REDUCE MRSA trial, 
which reported as-assigned adjusted hazard ratios of 0.98, 
0.77, and 0.55 for the screening and isolation, targeted de-
colonization, and universal decolonization strategies, respec-
tively.9 These results were relative to the pre-trial time period, 
in which all arms were performing screening and isolation. 
To compare the targeted decolonization and universal de-
colonization strategies to screening and isolation, we adjusted 
the results of those strategies so as to be relative to the long-
standing gold standard of screening and isolation.12 This re-
sulted in the relative risk of BSI being 1.00, 0.7857, and 0.5612 
for the screening and isolation, targeted decolonization, and 
universal decolonization strategies, respectively. 
TABLE i. Description of the Strategies to Prevent Intensive Care Unit (ICU) Bloodstream Infection Considered in the Cost Analysis 
Strategy Description 
Screening and isolation baseline strategy 
Targeted decolonization 
Universal decolonization 
Universal nares screening for MRSA carriage at ICU admission; use of contact precautions 
for MRSA carriers (by history or positive screening test result/clinical culture) 
Universal nares screening for MRSA carriage at ICU admission; use of contact precautions 
for MRSA carriers (by history or positive screening test result/clinical culture); decolo-
nize MRSA carriers with daily chlorhexidine baths and mupirocin treatment 
No screening for MRSA at admission to the ICU; use of contact precautions for MRSA 
carriers (by history or positive clinical culture); give daily chlorhexidine baths and mu-
pirocin to all patients in ICU 
NOTE. MRSA, methicillin-resistant Staphylococcus aureus. 
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TABLE 2. Decision-Analysis Model Inputs Derived from the REDUCE MRSA Trial: MRSA Colonization and Risk 
of Bloodstream Infection by Intensive Care Unit (ICU) Strategy 
Input parameter Base case Range 
Patients arriving at ICU who test positive for MRSA colonization or who have known 
MRSA history, by ICU strategy 
Screening and isolation* 11 5-20 
Targeted decolonization' 11 5-20 
Universal decolonization1" 4 4-20 
Baseline risk of bloodstream infection (screening and isolation strategy) per 1,000 
ICU admissions 19.63' 5-30 
Risk of any bloodstream infection, by strategy, relative to screening and isolation11 
Screening and isolation 1.0000 
Targeted decolonization 0.7857 0.6657-0.9157 
Universal decolonization 0.5612 0.4912-0.6512 
NOTE. Data are percentage of patients, unless otherwise indicated. MRSA, methicillin-resistant Staphylococcus aureus; 
REDUCE, Randomized Evaluation of Decolonization versus Universal Clearance to Eliminate. All estimates derived 
from Huang et al.9 
a
 Estimate based on the average baseline values reported by Huang et al.9 
b
 Estimate based on the trial results reported by Huang et al.9 This differs from the other strategies, because under 
the universal decolonization strategy, ICU screening was stopped and active decolonization was occurring for all 
patients. As the intervention progressed, patients who were readmitted may have been less likely to be identified as 
MRSA positive. Patients with an earlier ICU admission would be less likely to be screened for MRSA and less likely 
to acquire MRSA because of universal decolonization. In the trial, 47% of patients with a history of MRSA had a 
previous admission in the past year. The fact that this 4% value is lower than for the other 2 strategies does not imply 
anything about the "real" colonization rate. The only impact of this value on the cost results is that it means fewer 
persons are put on contact precautions under the strategy of universal decolonization. 
1
 Equivalent to 4.99 bloodstream infections per 1,000 ICU-days. 
d
 In the published report of the trial,9 the effectiveness of the strategies was reported relative to the baseline (prein-
tervention) period. We have here adjusted those results so as to make the screening and isolation strategy the reference. 
"Low" and "high" represent 95% confidence intervals. 
Model Inputs: Costs and ICU-Days 
Parameter estimates related to the base case are shown in 
Table 3. Intervention costs were derived from the literature. 
Intervention-related costs are the costs of screening, contact 
precautions, and decolonization. Where possible, preference 
was given to estimates that were more recent and were from 
the United States. The estimates used in most of the recent 
literature did not vary substantially, with the exception of the 
cost of an MRSA screening test and the cost of mupirocin. 
Variation in screening costs were primarily related to whether 
the screening was assumed to be performed using the more 
costly polymerase chain reaction (PCR) test or the less costly 
chromogenic agar culture. Variation in literature estimates of 
the cost of mupirocin primarily related to whether generic 
or trade mupirocin was assumed to be used. In our base case, 
we assumed the chromogenic agar culture was used for 
screening (as it was in nearly all hospitals of the REDUCE 
MRSA trial) and that generic mupirocin was used for de-
colonization. We also assumed that positive chromogenic agar 
cultures would not require confirmatory tests, and therefore 
we assumed no difference in screening costs between positive 
and negative screens. Any additional labor costs involved in 
applying mupirocin were assumed to be negligible, and be-
cause patients are typically bathed at least once a day as part 
of usual care, we assumed that the cost of bathing with chlor-
hexidine cloths does not require any additional labor. Cost 
estimates reflect the "steady state;" we did not attempt to 
estimate start-up costs, such as those that might be associated 
with training staff. All cost estimates are in SUS, adjusted to 
year 2012 using the consumer price index. 
We used estimates from the literature to estimate the in-
cremental hospital days and cost of a BSI (and therefore the 
incremental savings associated with preventing an infection). 
Hassan et al13 estimated that the incremental hospital-days 
associated with a hospital-acquired infection (not specifically 
BSI) was 3.296. In addition, they estimated that the cost of 
an additional hospital-day once an infection was acquired 
was 24% higher than the cost of an uninfected day. Dasta et 
al16 estimated that the mean cost of an ICU-day (after day 
3) was $4,385 (after adjusting to 2012 dollars). Applying the 
above estimates, we estimated the incremental cost of a BSI 
to be $17,920 (3.296 x [4,385 + (0.24 x 4,385)]). This 
estimate is consistent with the estimated incremental cost of 
BSIs reported by Kilgore et al25 ($22,371 in year 2012 dollars), 
who, like Hassan et al13, used a large US database and im-
plemented methods to control for heterogeneity and endo-
geneity biases. All differences among the 3 strategies in hos-
pital days and general ICU costs (not including intervention 
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TABLE 3. Decision-Analysis Model Inputs and Literature Sources, Base Case Scenario 
Input parameter Base case 
Range for 
sensitivity analyses 
Sources for 
base case, range 
Cost of screening test ($) 
Contact precautions 
Cost per gown ($) 
Cost per pair of gloves ($) 
Time to don and doff gown and gloves (minutes) 
No. of nurse visits per ICU patient-day* 
No. of physician visits per ICU patient-dayb 
Hourly wage, nurses 
Hourly wage, physicians 
Total cost per day of contact precautions 
Decolonization 
Cost of chlorhexidine impregnated cloths, 1 body wash ($) 
No. of daily baths with chlorhexidine cloths' 
Cost of twice-daily intranasal mupirocin for 5 days ($)d 
Incremental labor costs associated with decolonization' 
ICU-days 
Mean ICU-days for patients with negative MRSA screen without bloodstream infection' 
Mean ICU-days for patients with positive MRSA screen without bloodstream infection' 
Incremental ICU-days for persons with bloodstream infection, but due to additional 
comorbidities rather than infection per ses 
Mean incremental ICU-days due to bloodstream infection8 
Cost per ICU-day, days without bloodstream infection ($)h 
Incremental cost per ICU-day for patients with bloodstream infection ($)' 
Total incremental cost of bloodstream infection ($)' 
9.12 
0.96 
0.09 
1.00 
53.00 
13.00 
34.24 
89.46 
118.84 
5.35 
1.25 
7.32 
0.00 
4.15 
5.15 
3.46 
3.30 
4,385 
1,052 
17,920 
9.12-
1.00 
30 
6-
7.32-
2,880-
-48.24 
-2.00 
-53 
-13 
-93.92 
-35,000 
Fee schedule, fee schedule' 
Kang et al21 
Kang et al21 
Kang et al21; Puzniak et al22 
Kang et al21; Morgan et al2' 
Kang et al21; Morgan et al23 
Kang et al21 
Kang et al21 
Calculated 
Nelson et al15 
Assumption 
Courville24 
Assumption 
Trial data 
Trial data 
Hassan et al'J 
Hassan et a l" 
Dasta et al16 
Hassan et al13; Dasta et al"' 
Calculated; Roberts et al"; 
Kilgore and Brossette25 
NOTE. All costs are in $US and have been adjusted to the 2012 price level using the consumer price index. ICU, intensive care unit; PCR, polymerase 
chain reaction. 
* Base case assumes screening culture using chromogenic agar, assuming no extra cost for a positive result. High-range cost assumes use of PCR screening 
test. Cost estimates are national limit reimbursement from 2013 US clinical diagnostic laboratory fee schedule, available at http://www.cms.gov/Medicare/ 
Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/clinlab.html, HCPCS 87081, "Culture screen only," and HCPCS 87641 "Mr-staph dna amp probe." 
'' Base case visit counts were based on direct observation of staff at 3 Department of Veterans Affairs hospitals and 1 university teach hospital.23 The actual 
observed mean physician visits per ICU-day was 17, but it was estimated that approximately 25% of these visits were associated with the teaching function 
of the hospitals (Daniel Morgan, personal communication). We therefore assumed 13 mean physician visits per day. 
1
 Assuming 1 bath per day as routine, plus 0.25 baths per day to account for large patients, incontinence, and wastage. 
d
 Base case assumes use of generic mupirocin. High value is based on authors' analysis of average wholesale price for trade mupirocin. 
'' Assume negligible additional labor time for applying mupirocin and that use of chlorhexidine cloths requires no additional time relative to normal bath. 
' Estimates are from unpublished data from the Randomized Evaluation of Decolonization versus Universal Clearance to Eliminate [REDUCE] MRSA trial.' 
These lengths of stay were applied to the screening and isolation and targeted decolonization strategies. For universal decolonization, in which patients are 
not screened for MRSA colonization, the length of stays were calibrated so as to be the same as stays in the other 2 strategies, except for any reductions 
caused by prevention of bloodstream infections. 
8
 Estimates reported in Hassan et al13 were for all hospital-acquired infections and all units. We assumed these would apply to bloodstream infections that 
occurred in the ICU and that the additional hospital-days would be in the ICU. 
h
 Because we use this estimate for the incremental costs of additional days within a stay, we used the mean cost as reported by Dasta et al'6 for days 3 and 
later. The mean cost per ICU-day reported by Dasta et al16 was not specifically for uninfected days. However, given the relatively low incidence of hospital-
acquired infections (about 6% as reported in Hassan et al"), we treated this as a reasonable estimate for the cost of an uninfected ICU-day. 
1
 Percentage increase (24%) in uninfected cost per day as estimated by Hassan et al" applied to estimated cost per ICU-day of Dasta et al." 
1
 The low value of $2,880 is 16% of the base case estimate and is an estimate of short-run marginal costs that includes only healthcare worker supplies. 
costs) were assumed to be due entirely to differences in the 
incidence of BSIs and their effects on length of stay and cost 
per day. 
To test the sensitivity of the model results, we varied several 
important parameters (baseline incidence of BSI, reduction 
in BSI associated with universal decolonization, and incre-
mental ICU cost of BSI) over a wide range. In addition, we 
estimated the differences between the 3 screening strategies 
under a number of alternative scenarios to the base case. For 
example, we included a scenario in which the PCR test, rather 
than chromogenic culture, is used to test for MRSA, and a 
scenario in which trade, rather than generic, mupirocin is 
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TABLE 4. Costs, Length of Stay, and Cost Savings Associated with 3 Intensive Care Unit (ICU) Strategies 
to Reduce ICU Bloodstream Infection per 1,000 ICU Admissions, Base Scenario 
Strategy 
Baseline 
screening Targeted Universal 
Variable and isolation decolonization decolonization 
ICU admissions 
Total admissions to ICU 1,000 1,000 1,000 
No. of patients screened for MRSA at admission 1,000 1,000 0 
No. of patients screening positive for MRSA (or 
status is otherwise known at admission) 110 110 40 
No. of patients on contact precautions 110 110 40 
No. of patients decolonized 0 110 1,000 
No. of patients with any bloodstream infection 20 15 11 
ICU-days 
Total no. of ICU-days 4,391 4,377 4,362 
No. of patient-days with contact precautions 581 579 209 
Costs ($) 
Cost of MRSA screening tests 9,120 9,120 0 
Cost of contact precautions 69,010 68,830 24,890 
Cost of decolonization 0 4,679 36,500 
ICU costs, not including screening, contact pre-
cautions and decolonization 19,320,000 19,250,000 19,170,000 
Total cost 19,400,000 19,330,000 19,230,000 
Total cost per admission 19,400 19,330 19,230 
Incremental costs (savings) per admission com-
pared with screening and isolation ($) 
Intervention costs only (screening, contact pre-
cautions, decolonization) ... 4 (17) 
Bloodstream infection-related ICU costs ... (75) (155) 
All costs ... (71) (171) 
Incremental costs (savings) per admission com-
pared with screening and isolation ($) 
Intervention costs only (screening, contact pre-
cautions, decolonization) ... ... (21) 
Bloodstream infection-related ICU costs ... ... (79) 
All costs ... ... (100) 
NOTE. MRSA, methicillin-resistant Staphylococcus aureus. 
used for decolonization. Another scenario included only those 
costs estimated to be variable in the short run. In their study 
of variable versus fixed costs of hospital care, Roberts et al14 
treated labor and overhead as fixed in the short run and 
estimated that only 16% of all hospital costs (corresponding 
to healthcare worker supplies) were avoidable in the short 
run. Therefore, in this scenario, we assumed that the incre-
mental cost of a BSI was 16% of our base case estimate, and 
we assumed no incremental cost for labor to don and doff 
gowns and gloves. 
RESULTS 
Over the course of 1 year at a hospital with 1,000 annual 
adult ICU admissions, we estimated that a strategy of uni-
versal decolonization would prevent 9 BSIs compared with a 
strategy of screening and isolation (11 vs 20) and 4 BSIs 
compared with a strategy of targeted decolonization (11 vs 
15; Table 4). The universal decolonization strategy was esti-
mated to have the lowest mean intervention costs, saving $ 17 
per admission compared with screening and isolation and 
saving $21 per admission compared with targeted decolo-
nization. By preventing BSIs, the universal decolonization 
strategy was estimated to save $155 per admission in non-
intervention, ICU-related costs compared with targeted de-
colonization. In total, for every ICU admission, universal 
decolonization was estimated to save $171 compared with 
screening and isolation and $100 compared with targeted 
decolonization. 
These results were robust to changes in the parameter es-
timates that were derived from the REDUCE MRSA trial.9 
Figure 1A shows the estimated savings per admission (com-
pared with screening and isolation) of universal decoloni-
zation, assuming it was less effective at preventing BSIs than 
was reported in the REDUCE MRSA trial. Because the strategy 
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0.50 0.55 0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.95 
Relative risk ratio universal decolonization vs. Screening and 
Isolation 
5.00 10.00 15.00 19.60 25.00 30.00 
Baseline incidence of bloodstream infections per 1000 ICU admits 
5000 10000 15000 20000 25000 30000 
Incremental ICU cost per bloodstream infection ($) 
FIGURE i. One-way sensitivity analyses of the estimated cost savings of universal decolonization compared with screening and isolation 
per intensive care unit (ICU) admission when evaluating (A) the relative reduction (risk ratio) in bloodstream infections, (B) the baseline 
incidence of ICU bloodstream infections, and (C) the incremental cost of an ICU bloodstream infection. 
of universal decolonization was estimated to have lower in-
tervention costs than strategies involving screening, we es-
timated there would be modest cost savings even if it were 
not more effective in preventing BSIs than screening and 
isolation alone. Results were also robust to varying assump-
tions regarding the baseline incidence of ICU BSIs (Figure 
IB) and to the incremental cost of a BSI (Figure 1C). 
We estimated the differences between the 3 screening strat-
egies under a number of alternative scenarios to the base case 
(Table 5). Results were robust to a large number of plausible 
alterations in the assumptions. For example, if the more costly 
PCR test is used for MRSA screening, the universal decolo-
nization strategy saves $210 per ICU admission versus $171 
if chromogenic agar culture is used (scenario 1). If the more 
costly trade mupirocin is used for decolonization, the uni-
versal decolonization strategy saves $85 per ICU admission 
versus $171 if generic mupirocin is used (scenario 2). When 
including only costs estimated to be avoidable in the short-
term (ie, when all labor is considered to be a "fixed" cost in 
the time period under consideration), universal decoloniza-
tion saves $23 per ICU admission (scenario Ml) compared 
with screening and isolation. Only under the most pessimistic 
combination of assumptions did the universal colonization 
strategy cost more than the other two strategies. 
D I S C U S S I O N 
Universal decolonization has been shown to be a more ef-
fective strategy for reducing BSIs due to all pathogens than 
either MRSA screening and isolation or MRSA screening plus 
targeted decolonization.9 We now show that universal de-
colonization is also likely to reduce costs. Because savings 
come both from reductions in BSIs (and associated ICU sav-
ings) and from lower intervention costs, the benefits of uni-
versal decolonization are robust across a wide range of plau-
sible cost and effectiveness assumptions. Consistent with 
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TABLE 5. Sensitivity Analyses of Cost Savings of 3 Intensive Care Unit (ICU) Strategies to Reduce ICU Bloodstream Infection per 
1,000 ICU Admissions 
Cost (saving) 
per admission of 
universal decolonization, $US 
Compared with Compared with 
Scenario number and description screening and isolation targeted decolonization 
Base case (171) (100) 
One-way sensitivity 
1. Assume MRSA screening is done using polymerase chain reaction test ($48) (210) (140) 
2. Assume use of trade mupirocin ($94) (85) (23) 
3. Assume time to don and doff gloves and gown is 2 minutes (190) (119) 
4. Assume 30 nurse and 6 physician visits per ICU-day (151) (80) 
5. Assume no incremental labor costs associated with contact precautions (153) (82) 
6. Assume 20% of patients arriving at ICU under screening and isolation and (228) (160) 
targeted decolonization strategies have history of MRSA and are placed on 
contact precautions 
7. Assume 5% of patients arriving at ICU under screening and isolation and (134) (60) 
targeted decolonization strategies have history of MRSA and are placed on 
contact precautions 
8. Assume 10.8% of patients arriving at ICU under universal decolonization (128) (57) 
have history of MRSA and are placed on contact precautions (ie, the same 
percent as for the other strategies) 
9. Assume incremental cost of bloodstream infection is $2,880 (estimate of (41) (34) 
short-run variable costs) 
10. Assume incremental cost of bloodstream infection is $35,000 (299) (166) 
11. Assume relative risk of bloodstream infection in universal decolonization (196) (125) 
strategy compared with screening and isolation strategy is 0.4912 (rather 
than 0.5612) 
12. Assume relative risk of bloodstream infection in universal decolonization (140) (69) 
strategy compared with screening and isolation strategy is 0.6512 (rather 
than 0.5612) 
Multiway sensitivity 
Ml. Include only those costs estimated to be short-run variable costs (scenar- (23) (16) 
ios 5 and 9) 
M2. Combine assumptions least favorable to universal decolonization strategy 94 92 
(scenarios 2, 5, 8, 9, and 12)" 
M3. Combine assumptions most favorable to universal decolonization strategy (507) (367) 
(scenarios 1, 4, 6, 10, and 11) 
NOTE. Data differ from those given in the text due to rounding; data in parentheses are savings. MRSA, methicillin-resistant Staph-
ylococcus aureus. 
' Scenario 7 was excluded because it was considered implausible for the universal decolonization strategy to have a higher percentage 
of patients on contact precautions given that no MRSA testing is performed in this strategy. 
other studies,15 we also found that a strategy of screening and 
targeted decolonization, although not as cost-beneficial as 
universal decolonization, also resulted in lower costs and 
fewer BSls than screening and isolation alone. 
For a hospital with 1,000 ICU admissions per year, we 
estimate that universal decolonization would prevent 9 BSIs 
and potentially save approximately $171,000 annually com-
pared with screening and isolation. The majority of the es-
timated savings ($155,000) are associated with expected 
reductions in BSIs. Because the combined cost of chlorhex-
idine-impregnated cloths and generic mupirocin is similar to 
the cost of screening cultures, the balance of the savings 
($17,000) is primarily related to savings from reducing the 
number of patients placed on contact precautions. Using our 
base case cost assumptions, intervention costs will be similar 
under both strategies only if the percentage of patients placed 
on contact precautions is similar, which is highly unlikely 
given the lack of screening testing under universal decolo-
nization, or if we assume no incremental labor costs for don-
ning gloves and gowns. 
A strategy of universal decolonization has been shown to 
reduce BSIs by over 40%,9 and most of the savings from 
implementing that strategy would come from reducing BSIs 
and the associated ICU-days. The magnitude of the actual 
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savings at any given institution will largely depend on the 
ability to realize cost reductions from fewer infections. Using 
estimates from the literature, we assumed that each infection 
prevented would avert 3.3 ICU-days and potentially save 
$18,000. The estimated cost per ICU-day that we used was 
based on hospital charges that were then adjusted downward 
by cost-to-charge ratios.16 As such, it may be thought of as 
an estimate of long-run average cost. For any given hospital, 
the savings from averting infections is likely to be substantially 
less and will depend, for example, on staffing flexibility and 
the value of alternative uses for the freed-up bed-days.1718 
Nevertheless, the cost-savings of the universal decoloni-
zation strategy should be realized even by those institutions 
with excess capacity or staffing that is hard to reduce in the 
short term. Even when using a very conservative estimate of 
variable costs (one not including any labor costs), universal 
decolonization still dominates the other 2 strategies. We note 
also that our analysis is otherwise conservative in that we 
have not included any productivity or time costs associated 
with reduced morbidity. 
In addition, because overall intervention costs were similar 
or lower in our base case estimates, the universal decoloni-
zation strategy was the most cost-saving strategy, even under 
assumptions of minimal effect in reducing BSIs compared 
with screening and isolation alone. 
The effectiveness estimates for the prevention strategies 
were derived from a single trial that included mostly com-
munity hospitals, although they were largely representative 
of US hospitals.* Results could vary in hospitals with different 
patient characteristics, such as proportion of MRSA carriage, 
or different BSI rates. (The REDUCE MRSA trial focused on 
community hospital ICUs that may have lower BSI rates than 
ICUs in academic or specialty cancer care hospitals.) Nev-
ertheless, our sensitivity analyses indicate that the results were 
robust to changes in those parameters. We did not measure 
the absolute savings of each strategy compared with no in-
tervention. Among the hospitals in the REDUCE MRSA trial, 
screening and isolation was the longstanding gold standard,12 
and that is the strategy to which the other strategies were 
compared. Any gains attained by screening and isolation be-
fore the baseline period were not quantified. Nevertheless, 
the cost savings of the universal decolonization arm over 
screening and isolation alone and targeted decolonization is 
valid. Because we used a static model, we could not explicitly 
account for possible changes in resistance or herd effects. 
However, the results of the trial upon which our base case 
epidemiological assumptions were based incorporated those 
effects to the extent that they occurred during the period of 
the trial. The use of a static model also meant that sensitivity 
analyses (for example, those in which the incidence of BSIs 
were varied) were not dynamically linked to other parameters, 
such as MRSA carriage rates, to which they might, in actuality, 
be related. 
Widespread and long-term use of chlorhexidine and mu-
pirocin may engender drug resistance.19'20 From the perspec-
tive of this study, increased resistance would be tantamount 
to reduced effectiveness of universal decolonization. However, 
the effect of universal decolonization on reducing BSIs does 
not need to be large for that strategy to be preferred. Finally, 
our perspective was primarily that of the healthcare system 
and resource use, and so we did not address issues relating 
to hospital reimbursement. 
A strategy of universal decolonization for patients admitted 
to the ICU would both reduce BSIs and likely reduce health-
care costs compared with strategies of MRSA nares screening 
and isolation or screening and isolation coupled with targeted 
decolonization. These findings were robust to a wide range 
of cost and effectiveness assumptions. 
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